PRESS RELEASE 2025
-
Ferring Presents New Phase 3b Safety and Effectiveness Data for Recurrent C. Diff Patients Receiving REBYOTA® (fecal microbiota, live – jslm) Via Colonoscopy, and Additional Analyses at DDW
Data presented at Digestive Disease Week (DDW) 2025 demonstrated safety and treatment success in patients treated for recurrent C. Diff infection with REBYOTA administered by colonoscopy Data also showed improvement in quality of life and daily functioning Additional findings from the PUNCH clini...
-
U.S. FDA Approves Second Drug Product Manufacturing Facility for ADSTILADRIN® (nadofaragene firadenovec-vncg)
Ferring expands production of ADSTILADRIN with new Parsippany, NJ, facility, adding to existing manufacturing sites in Kuopio, Finland Capacity expansion and diversification of manufacturing footprint further ensures stable and sustainable supply to meet the anticipated growth in global demand fo...
-
Ferring Unveils New Data with ADSTILADRIN® (nadofaragene firadenovec-vncg) at 112th Annual Meeting of the Japanese Urological Association
First results from a Phase 3 trial conducted across 25 centers in Japan highlight Ferring’s ongoing commitment to establish ADSTILADRIN as the new standard of care and backbone therapy for non-muscle invasive bladder cancer (NMIBC)1 Results showed 75% complete response rate at three months in hi...
-
First Real-World Outcomes Data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be Presented at 2025 ASCO Genitourinary Cancers Symposium
Independent experience at three Mayo Clinic sites and real-world outcomes data with ADSTILADRIN in patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented at ASCO GU 2025 Protocols for two ongoing studies from the ADSTILADRIN ...
-
Ferring Highlights Commitment to C. Diff Infection Community on the Second Anniversary of the Launch of REBYOTA® (fecal microbiota, live – jslm)
FDA approved to prevent recurrent C. difficile infection (rCDI), REBYOTA is widely available with a strong drug supply and dedicated manufacturing facility Since launch, Ferring created REBYOTA @ Home to help patients with rCDI across the U.S. receive treatment at home as well as health care sett...